Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.
TNDM
Tandem Diabetes Care, Inc. · NASDAQ
Sign up free to see this.
Mkt Cap
$1.2B
Volume
1.4M
52W High
$29.65
52W Low
$12.26
PE Ratio
—
Avg Vol
2.2M
As of 10/23/26
Div Yield
—
Beta
0.92
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about TNDM?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $TNDM · 0 threads
Sign in to post on $TNDM
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.